Precision (aka personalised) medicine is an emerging approach that takes into account individual variation to predict which treatment/prevention strategies will work in which groups of people. For example, colon cancers that have a normally functioning version of a surface protein called KRAS are likely to respond to certain anti-EGFR antibody therapies; those in which the protein is absent or non-fun. Successful innovation in precision medicine requires several sectors (academia, healthcare and industry) work together - often easier said than done. P4 sits at the intersection of these sectors, leveraging our academic, industry and healthcare connections to create a healthtech ecosystem to supercharge the development and scale of precision medicine technologies. Our flagship “accelerator” programme is the first of its kind in the UK, and is a partnership with UCL and Barclays. The first cohort in the accelerator are nearly half-way through the 12 month programme. So far, the accelerator has supported these 11 companies to raise £30million, receive 9 research grants and hire 7 new employees. The accelerator provides start-ups with personalized connections and introductions, as well as other support including workshops, personalised coaching (grant writing, AI and IP/regulations), testbeds and trial opportunities and regulatory pathway support to CE marking. Applications for the second cohort are open at p4precisionmedicine.co.uk/apply